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Abstract
Notwithstanding the many advances made in cancer research over the last
several decades, there are still many fundamental questions that need to be
addressed. During my PhD, I have been working on developing statistical
methods to analyze liquid biopsy data for cancer early detection and using
mathematical modeling to better understand cancer etiology.
Traditionally, cancer-causing mutations have been thought to have two
major sources: inherited (H) and environmental (E) risk factors. However,
these are not enough to explain the extreme variation in cancer incidence
across different tissues. Recently, the random mutations occurring during nor-
mal cell replications (R mutations) were recognized as a third and important
source of cancers. In the first part of this dissertation, we proposed a novel
approach to estimate the proportions of these three sources of mutations using
cancer genome sequencing and epidemiological data. Our method suggests
that R mutations are responsible for two-thirds of the mutations in human
cancers or at least not less than 40% of them.
At the same time, while the role of driver mutations and other genomic
alterations in cancer causation is well recognized, they may not be sufficient
for cancer to occur. Other factors like, for example, the immune system
ii
and the microenvironment, also have their impacts. It’s not known, as of
now, how large is the contribution of mutations compared to all these other
factors, which we collectively define as K factors. Therefore, the second part
of this dissertation is trying to address this question. We develop a method
to estimate how much of the observed increase in cancer risk due to a E or H
factor can be explained by the increase in mutation rate caused by that factor,
thus providing an assessment of the role of mutations during tumorigenesis.
Genome sequencing and epidemiological data are used to perform the analysis.
Our results show that the higher mutation rate is able to explain the majority
of the increase in cancer risk due to smoking and microsatellite instability
(MSI), a moderate fraction in Hepatitis C (HCV) infections, but almost nothing
when considering obesity.
Overall, the above results indicate that a relevant amount of cancers may
not be preventable due to the unavoidable R mutations. Thus, in addition
to finding new therapies, it seems critical to be able to detect cancers earlier
in order to reduce cancer deaths. In the third part of this dissertation, we
develop statistical methods to analyze genome sequencing data for the early
detection of cancer. Combining mutational information with protein assays,
the median sensitivity of our method is 70% in eight cancer types, including
ovary, liver, stomach, pancreas, esophagus, colorectum, lung, and breast, with
99% specificity. The sensitivities range from 69% to 98% for the detection of
five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which
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1.1 Cancer mortality, etiology, and prevention
It is estimated that the number of new cancer cases for 2018 in the US is
over 1.7 million (SEER). With an aging population, this number is likely to
increase in the future. 609,640 Americans are expected to die of cancer in 2018,
which makes cancer the second most common causes of death in the US, only
exceeded by heart disease (Cancer Facts and Figures 2018). And when consider-
ing the last fifty years, the decrease in cancer mortality rates among developed
countries is much smaller than the decrease in mortality rates observed for
heart disease (Wang et al., 2016). From a public health perspective, this then
presents the challenge of having better strategies on cancer prevention, which
in turn requires a better knowledge of cancer etiology. Environmental (E) and
inherited factors (H) are by far the most well-accepted cancer causes. For
example, an estimate of 80% to 90% of the lung cancers in the US are linked
to cigarette smoking (Centers for Disease Control and Prevention). The role of
hereditary factors have been demonstrated from both twin studies (Mucci
1
et al., 2016) and the identification of the genes responsible for cancer predispo-
sition syndromes (Vogelstein et al., 2013). Recently, a third source - mutations
due to the random mistakes made during normal DNA replication (R) - has
been proposed to explain the variation in cancer risk among different tissues
(Tomasetti and Vogelstein, 2015), and overall R mutations seem responsible
for a large fraction of the mutations found in human cancers(Tomasetti, Li,
and Vogelstein, 2017).
Prevention of any disease can be classified into primary prevention and
secondary prevention (Song et al., 2018). Primary prevention is the interven-
tion before any disease happens, by using vaccines, avoiding risky behaviors
and substances known to be related to a disease, while secondary prevention
is the detection and intervention at the early stage of the disease. Primary
prevention is undoubtedly the best way to reduce cancer deaths, but is not
currently available for all cancer types. For cancers without effective primary
prevention strategies, early detection appears to be the key to reduce cancer
deaths. With the advancement of sequencing technologies, liquid biopsies
are becoming an important and promising research direction, given the ben-
efits of being non-invasive, relatively quick, and easily repeatable tests. An
example of a recent blood test developed for cancer early detection is (Cohen
et al., 2018). The new type of data generated by liquid biopsies require the
development of new methods for their analysis.
2
1.2 Structure of the dissertation
In this dissertation, we apply modeling techniques to address some of the
important questions on cancer etiology and develop statistical methods for
liquid biopsy data in cancer early detection. The rest of the thesis is organized
as follows.
In Chapter 2, we introduce a novel approach to quantify the fractions
of mutations due to environmental factors, inherited factors and random
mutations. We used epidemiology data and genome sequencing results to
evaluate the hypothesis that R mutations play a major role in cancer. The result
explicitly and quantitatively address the difference between cancer etiology
and cancer preventability.
In Chapter 3, we propose a method to assess the role of mutations in
cancer causation. It is known that mutations represent a necessary ingredient
for cancer to occur. But it may not be sufficient. This part of the work is
trying to find how large is the contribution of mutations when compared
to other important factors like, for example, the immune system and the
microenvironment.
In Chapter 4, we illustrate a method for analyzing the data from a blood test
for the early detection of cancers of ovary, liver, stomach, pancreas, esophagus,
colorectum, lung and breast. This method provides of a median sensitivity
of 70% among the eight cancer types, at the specificity level of 99%. The
sensitivities ranged from 69% to 98% for cancers (ovary, liver, stomach, pan-
creas, and esophagus) for which no screening tests are currently available for
3
average-risk individuals.
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Chapter 2
Estimation of proportions of
mutations using EHR model
2.1 Introduction
It is now widely accepted that cancer is the result of the gradual accumu-
lation of driver gene mutations that successively increase cell proliferation
(Garraway and Lander, 2013; Stratton, Campbell, and Futreal, 2009; Vogelstein
et al., 2013). But what causes these mutations? The role of environmental
factors (E) in cancer development has long been evident from epidemiolog-
ical studies, and this has fundamental implications for primary prevention.
The role of heredity (H) has been conclusively demonstrated from both twin
studies (Mucci et al., 2016) and the identification of the genes responsible for
cancer predisposition syndromes (Vogelstein et al., 2013; Stadler et al., 2010).
A recently study hypothesized that a third source - mutations due to the
random mistakes made during normal DNA replication (R) - can explain why
cancers occur much more commonly in some tissues than others (Tomasetti
and Vogelstein, 2015b). This hypothesis was based on the observation that,
7
in the United States, the lifetime risks of cancer among 25 different tissues
were strongly correlated with the total number of divisions of the normal
stem cells in those tissues (Tomasetti and Vogelstein, 2015b; Tomasetti and
Vogelstein, 2015a). It has been extensively documented that approximately
three mutations occur every time a normal human stem cell divides (Lynch,
2010; Tomasetti, Vogelstein, and Parmigiani, 2013). Therefore, the authors
inferred that the root causes of the correlation between stem cell divisions and
cancer incidence were the driver gene mutations that randomly result from
these divisions. Recent evidence from mouse models supports the notion that
the number of normal cell divisions dictates cancer risk in many organs (Zhu
et al., 2016).
However, this analysis was confined to explaining the relative risk of can-
cer among tissues rather than the contribution of each of the three potential
sources of mutations (E, H, and R) to any single cancer type or cancer case
(Tomasetti and Vogelstein, 2015b). Determination of the contributions of E,
H, and R to a cancer type or cancer case is challenging. In some patients, the
contribution of H or R factors might be high enough to cause all the mutations
required for that patient’s cancer, whereas in others, some of the mutations
could be due to H, some to R, and the remainder to E. Here we perform a
critical evaluation of the hypothesis that R mutations play a major role in
cancer. Our evaluation is predicated on the expectation that the number of
endogenous mutations (R) resulting from stem cell divisions in a tissue, unlike
those caused by environmental exposures, would be similarly distributed
at a given age across human populations. Though the number of stem cell
8
divisions may vary with genetic constitution (e.g., taller individuals may have
more stem cells), these divisions are programmed into our species’ develop-
mental patterns. In contrast, deleterious environmental and inherited factors,
either of which can directly increase the mutation rate or the number of stem
cell divisions, vary widely among individuals and across populations. To
perform the evaluation, we developed a novel approach to determine what
fractions of cancer-causing mutations result from E, H, or R. These fractions
have not been estimated for any cancer type previously.
2.2 Method
2.2.1 Single Environmental Factor
We define T as the total number of (clonal) somatic mutations present in
the tumor cell that acquired the last of the driver gene mutations required to
yield a given cancer, i.e. the founding cell of the final clonal expansion. First,
consider cancers in patients not affected by any deleterious environmental
(E) or inherited (H) factor. Given our definition of replicative (R) mutations,
the number of somatic mutations that occur in a tissue independently of the
deleterious effects of environmental (E) or inherited (H) factors are assigned
to R. It follows that in those cancers from patients not exposed to any E and H
factors, all the required driver mutations, as well as all passenger mutations,
occurring before and during the tumor’s clonal expansions are due to R. The








where M is the total number of divisions of the cell until it acquired the last
driver gene mutation, and md is the number of somatic mutations occurring
at dth cell division, with d = 1, ..., M. Note that both M and all md are random
variables, and that the resulting random variable TR > 0 because at least
one driver gene mutation is required to develop a cancer. By considering a
population of cancer patients only affected by R, we obtain a distribution for
the total number of somatic mutations, TR, in the unexposed population.
Next, consider the case where only one environmental (E) factor and no
inherited (H) factors affect a cancer’s incidence. For patients exposed to this
harmful environmental factor E at the same level, the total number of somatic









with M′ ≥st M, or m′ ≥st m, or both, where ≥st stands for stochastically
greater and TE >0.
Intuitively, E is expected to either increase the number of somatic mutations
that occur in each cell division (e.g., a mutagen that acts directly on DNA)
or to increase the rate of cell division itself (e.g., smoking can inflame the
lungs, causing higher cell turnover), or both, thus increasing the rate at which
the cells acquire somatic mutations. It does not matter which one of the
two occurred or whether both occurred. What matters is that it occurred, as
measured through sequencing. The total number of somatic mutations, which
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are almost all passenger mutations, are akin to a clock that measures both
the number of divisions and the mutation probabilities: doubling the number
of cell divisions yields on average two times more mutations after a given
period, just as doubling the mutation rate does over that time period, all other
things being equal. Similarly, a doubling of the division rate (or a doubling of
the probability of mutation per cell division per base), if applied only to half
of the time interval before the founder cell is born, yields 12 ∗ 1 + 12 ∗ 2 = 1.5
times more mutations on average, all other things being equal. Note that
even the effect of a single event, occurring in a very short time interval (e.g.
seconds), such as a one-time exposure to a strong radiation source increasing
md by many fold, will be appropriately recorded in this sum. Basically, we do
not know the specific values for M and each md, but from sequencing data we
can observe the output of a sum, TE, which summarizes the mutational life
history of the cancer cell’s lineage.
When comparing TE and TR in cancer patients diagnosed at the same age a,
TE(a) ≥st TR(a) because the incidence of that cancer in the exposed group is
greater than in the unexposed group. Consider now what happens when we
sample two cancer patients P1 and P2 diagnosed at the same age, one who was
exposed to E (P1) and one who was not (P2), where tE is the specific realization
of TE(a) in P1 and tR is the realization of TR(a) in P2, with tE(a) ≥ tR(a). We







where the first term in the sum is the proportion of mutations that patient P1
11
would have had even if unexposed to E (i.e. attributable to R), assuming P1
would have had in that case the same total mutational load of P2, while the
second term in the sum is the proportion of extra mutations that P1 acquired
due to exposure to E. Obviously we cannot assume that P1 would have had
exactly the same mutational load of P2 if P1 was unexposed, because both
TE(a) and TR(a) are random variables rather than single fixed values, and
in fact it is possible that TE(a) < TR(a) in some pairs of patients. However,
given the distribution of TR(a) among all unexposed patients, it is true that,







and the distribution of the random variable min(TR(a)tE(a) , 1) is the distribution
of the proportion of mutations attributable to R in patient P1. Analogously,
1−min(TR(a)tE(a) , 1) is the distribution of the proportion of mutations attributable
to E in patient P1. As TE(a) ≥st TR(a), the average proportion of mutations
attributable to R and to E at the population level can be estimated by taking the
expected value of the above expression (in Equation 2.1 below, "E" denotes the









Therefore, for the population of patients of age a that were exposed to envi-
ronmental factor E, we can on average attribute the first term in the sum to
R, i.e. assign the average proportion E(TR(a)TE(a) ) of the overall mutation load
to R, and attribute the second average proportion to environmental factor
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E. Importantly, these same proportions can be used to attribute the average
proportions of driver gene mutations (rather than total mutations) to R and E
at the population level.
In practice, we will use the median instead of the mean for robustness -
the distribution of the total number of somatic mutations in tumors typically
has a large right tail (e.g. due to patients with defective mismatch repair
mechanisms). And we will control for age by dividing the specific T of
patients by their ages a. Given n cancer patients exposed to E and m cancer





), i ∈ {1, . . . , n}, j ∈ {1, . . . , m}
with its 95% confidence interval, as estimated via bootstrap. MR > 1 implies
that a larger average number of mutations had accumulated in the founder
cells of the cancers of the patients exposed to E than in unexposed patients
after controlling for age. In other words, cancers in patients exposed to E had





+ (1 − 1
MR
)
As before, it follows that in those exposed to the E factor, 1MR of the mutation
load can be attributed on average to R, and MR−1MR can be attributed to the
extra effects of E. The same is true for the proportion of driver gene mutations
(rather than total mutational load) attributable to R and E factors. Thus, we
define MEPAR, the mutational extrinsic proportion of attributable risk caused
13




MEPAR represents the median proportion of driver genes mutations that are
attributable to the extrinsic factor E in patients that are exposed to E.
For a given cancer type, we further define PPE, the proportion of cancer
patients exposed to environmental factor E, as
PPE =
Pe · RR
1 + Pe · (RR − 1)
where Pe is the prevalence of E in the general population, RR is the relative
risk of people getting a given cancer due to exposure of E comparing to people
unexposed to E. Thus, to estimate PE, the fraction of mutations attributed to E
in the cancer population, we have




and the proportion PR of the driver mutations required to develop this type of
cancer and attributable to R, is given by
PR = 1 − MEPAR · PPE =
1
MR
· PPE + 1 · (1 − PPE) (2.3)
The first term in the sum on the right side of Equation 2.3 is the proportion
of driver gene mutations attributable to R in patients exposed to E, and the
second term in the sum is the proportion of the driver gene mutations caused
by R in patients not exposed to E (which is always 100%). Note that this
equation does not require that every cancer patient has the same number
14
of required driver mutations as long as the distribution of the number of
required driver mutations is the same in patients with a given cancer type,
independently of E. Also, the same method can in principle be applied to
multiple quantiles of the distribution of the ratio rather than only to the
median MR. For example, if ten equidistant quantiles are used, each of those
quantile values will have a 0.1 weight in estimating the ratio. Importantly, for
the examples provided below, using the median MR is essentially the same or
more conservative than using multiple quantiles.
If we let PE be the proportion of driver gene mutations due to the E factor,
i.e. PE = 1 − PR, then the proportion of attributable risk (PAR, also known as
PAF), is
PAR =
Pe · (RR − 1)










MR − 1 · PE
This expression indicates the relationship between the proportion of cancers
cases that are preventable, PAR, and the proportion of driver gene muta-
tions that are attributable to the E factor, i.e. the relationship between cancer
preventability and cancer etiology. Importantly, PAR> PE, given that RR >
MR.
2.2.2 Generalization to Multiple Factors
Until now, we have been looking at the simplest case where only one
environmental factor is present for a given cancer type. Now, we generalize
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the above results to a more practical scenario, where multiple environmental
factors could affect the incidence of a specific cancer.
Let k, j, e be indexes respectively for the cancer type, age group and E
factor, among the possible E factors known to affect cancer type k. Let wj be
the proportion of the general population for age group j, Ik,j be the incidence
of cancer type k among population for age group j. Let ie be the exposure level
of factor E (there might be different levels of one factor, e.g. exercise level).
Consider for each cancer type k and for each age group j, a partition with index
δk,j of the cancer patient population in that age group, where each element
of the partition represents patients with a unique combination of exposure
levels across all environmental factors that have an effect on cancer type k. The
total number of partitions is given by the numbers of environmental factors
associated with cancer k and the numbers of levels for each related factors.
For example, if there are three factors known to have effects on cancer type k,
and these three factors each has 3,4,5 different exposure levels respectively,
then the total number of partitions is 3 · 4 · 5 = 60, i.e. δk,j will assume values
from 1 to 60.
Define Pδk,j as the proportion of patient with cancer type k within age group






1 + ∑i(Pej,ie (RRk,ie − 1))
where Pej,ie , according to the definition of PPE, is the prevalence in the general
population, in age group j with E factor e at exposure level ie, and RRk,ie is the
relative risk of cancer k for those exposed to factor e at exposure level ie.
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Define MRk,ie as the median ratio of the number of mutations, adjusted
for age, of those exposed to factor e at exposure level ie, and those unexposed,
in cancer k. To be conservative, we assume that different factors have multi-
plicative effects on cancer risk, then the proportion of drive gene mutations





















Hence, we can get the estimate of overall proportion of driver gene mutations
attributable to E across all cancer types, PE, where each cancer type k is























Having estimated PE, the last step is to obtain PH (see Section 2.2.4 for the
method). It then follows that the residual proportion of driver gene mutations
can be attributed to PR
PR = 1 − (PE + PH) (2.6)
Equations 2.4, 2.5 and 2.6 can be used to get the gender-specific estimates
of PE, PH, and PR. It is also possible to obtain the estimates combining both
17



































2.2.3 Determination of MR when cancer genome sequencing
data is not available
Previously, we discuss how to get the estimate of MR when sequencing
data is available. However, genome-wide sequencing data of cancers from
patients exposed and unexposed to specific environmental factors is generally
not available, so there is no experimentally derived estimate of MR. In this
section, we describe the method that conservatively estimates MR for any
environmental factor that is based simply on epidemiological data about the
relative risk (RR) conferred by that factor. This approach is applicable to the
very large number of cancer types that have been investigated extensively
through sophisticated epidemiologic techniques (e.g., those summarized in
Cancer Research UK, 2018b).
If x is the increase in mutation rate resulting from exposure to an environ-
mental factor, then a mathematical bound for x is provided by x ≤ RR 12 when
two driver gene mutations are required for cancer formation (Tomasetti et al.,
2015). Intuitively, a x-fold increase in the mutation rate would result in an x2
18
fold increase in cancer incidence because of the well-known exponential rather
than linear relationship between cancer incidence and age. The inequality
reflects the fact that there may be other deleterious effects (e.g. epigenetic)
induced by that environmental exposure that also increase RR by some factor
c, either additively (i.e. RR = c + x2 with c > 0) or multiplicatively (i.e.
RR = c · x2, with c > 1). We estimated MRs under the assumption that there
were no other deleterious effects; this assumption is conservative because
deleterious effects would lower the estimated MRs. Similarly, when three
mutations are required for cancer formation, we can assume x ≤ RR0.4. An
exponent of 0.4 is used in this case by assuming that each successive driver
gene mutation doubled the proliferative fitness advantage, as explained in
(Tomasetti et al., 2015; Durrett and Moseley, 2010). For most common can-
cers, the minimum number of driver gene mutations required for cancer
development is likely to be 3 (Tomasetti et al., 2015), and this minimum is
strongly supported by genome-wide sequencing studies on tens of thousands
of cancers (Garraway and Lander, 2013; Stratton, Campbell, and Futreal, 2009;
Vogelstein et al., 2013).
When applied to lung adenocarcinomas and pancreatic ductal adenocarci-
nomas, the increase in mutation rates caused by smoking can then calculated
to be 180.4 = 3.2 in lung adenocarcinomas, and 20.4 = 1.32 in pancreatic
ductal adenocarcinomas. Though based exclusively on epidemiological data,
these numbers are remarkably close to the estimates of x obtained experimen-
tally from genome-wide sequencing: 3.23 and 1.16 for lung adenocarcinomas
and pancreatic ductal adenocarcinomas, respectively, providing experimental
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validation of our heuristic.
2.2.4 Determining Oncogenic Viruses and Heredity Effects
Assume that a given cancer type requires n driver mutations to occur and
that those with a given hereditary predisposition to that cancer already have
one of those required driver gene mutations. Then, 1n of the required driver
mutations would be caused by this H factor. To be conservative, we attributed
1
2 of the total driver gene mutations to H in all these cases, even in solid cancers,
in which a minimum of three driver gene mutations is likely to be necessary
for cancer formation. Similarly, in those exposed to a virus, such as HPV 16 in
patients with cervical cancers, we attribute 23 of the required driver mutations
to that factor. The effects of these oncogenic viruses can be considered to be
mutations (i.e., changes in the DNA) because they are associated with the
insertion of viral oncogenes into the nucleus. The reason for attributing 23
to such viral infections is that the protein products of oncogenic viruses like
HPV inactivate two driver gene pathways (TP53 and Rb; McLaughlin-Drubin,
Meyers, and Munger, 2012). In other virally-associated cancers where the
molecular pathogenesis is not as clear, such as in liver cancers associated
with HBV infection, it is conservative to assume that 23 of the driver gene
"mutations" are contributed by the virus.
2.3 Data
The epidemiological information (prevalence Pe, relative risk RR, and
incidence I) for E factors known to affect 32 cancer types was obtained from the
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UK Cancer Research database (Cancer Research UK, 2018b; Cancer Research
UK, 2018c; Parkin, 2011). Whenever the prevalence was not indicated for a
given age interval (typically the youngest group), we conservatively attributed
to that environmental factor the prevalence of the adjacent age group. Kaposi
sarcoma was not included because incidence rates were not provided (an
extremely rare cancer). Given that UK epidemiological data were used, we
also used the weights w of the general U.K. population (all individuals, not
just cancer patients) for each age group and for each gender (UK Office for
National Statistics, 2015). To be conservative, environmental factors for which
epidemiological information was not fully available (specifically: second-hand
smoking, radiation, lack of breastfeeding, and occupational exposures) were
assumed to have the same, large effect on the mutation rate (i.e. same MR)
that smoking has on lung cancer, with PPE approximated by their PAR. Due
to the lack of data on the prevalence of various salt consumption levels, we set
the average consumption level of salt with PPE = 1 and compared it to the
recommended level of 6g per day to obtain MR. After obtaining estimates for
the PPEs and MRs for all known risk factors, Equations 2.4 and 2.5 were used
to obtain sex-specific estimates of PE, for each cancer type. Similarly, Equations
2.7 and 2.8 above were used to obtain estimates of PE when combining the
two sexes. Two thirds of the required driver gene mutations were attributed
to viral infections in cancers associated with viruses, with PPE approximated
by PAR, and added to the overall PE.
Information on the proportion of cancer cases attributable to inherited
factors (H) was obtained from the UK Cancer Research database (Cancer
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Research UK, 2018a), and if no estimate was available, 1% was assumed. It
is estimated that, overall, inherited mutations play a role in 5-10% of cancer
cases (National Cancer Institute, 2018). Thus, 10% of cancer cases were overall
conservatively attributed to H (i.e. PAR = 0.10) when deriving the estimates
of PH combined over all cancer types. As described above, we conservatively
attributed half of the driver gene mutations to H (i.e. PH = 0.5) in every cancer
case attributed to H.
Having estimates for PE and PH, Equation 2.6 was then used to estimate
PR, in each cancer type. We assumed that the number of driver genes re-
quired for cancer development was three in 25 of the 32 cancer types. The
seven exceptions were cancers of the bone, testes, myelomas, retinoblastomas,
leukemias, Hodgkin and non-Hodgkin lymphomas, in which we assumed
that two driver gene mutations were required for cancer. This assumption is
based on molecular genetic and epidemiological data indicating that fewer
driver gene mutations are required for the development of "liquid tumors"
and pediatric cancers than for solid tumors (Vogelstein et al., 2013).
2.4 Results
We calculated the proportion of drive gene mutations caused by E or H in
32 cancer types. We considered those mutations not attributable to either E
or H to be due to R. Figure 2.1 and Figure 2.2 show our estimates for females
and males respectively. When looking across the 32 cancer types, the median
proportion of driver mutations attributable to E was 23%. The estimate varied
considerably: it was greater than 60% in cancers such as those of the lung,
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Figure 2.1: Etiology of driver gene mutations in women with cancer For each of 18
representative cancer types, the schematic depicts the proportion of mutations that are
inherited, due to environmental factors, or due to errors in DNA replication (i.e., not
attributable to either heredity or environment). The sum of these three proportions
is 100%. The color codes for hereditary, replicative, and environmental factors are
identical and span white (0%) to brightest red (100%). B, brain; Bl, bladder; Br, breast;
C, cervical; CR, colorectal; E, esophagus; HN, head and neck; K, kidney; Li, liver;
Lk, leukemia; Lu, lung; M, melanoma; NHL, non-Hodgkin lymphoma; O, ovarian; P,
pancreas; S, stomach; Th, thyroid; U, uterus.
esophagus, and skin and 15% or less in cancers such as those of the prostate,
brain and breast. When normalized for the incidence of each of these 32
cancer types, we calculated that 29% of the mutations in cancers occurring
in the UK were attributable to E, 5% of the mutations were attributable to
H, and 66% were presumably attributable to R. The numerical results and
the values used to construct Figures 2.1 and 2.2 are provided in Table 2.1. In
addition, UK Cancer Research estimates that 42% of these cancer cases are
preventable. Given the relationship between PAR and PE we provided above,
the proportion of mutations caused by environmental factors is always less
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Figure 2.2: Proportion of driver gene mutations attributable to H, R, and E in men
with cancer For each of 16 representative cancer types, the schematic depicts the
proportion of mutations that are inherited, due to environmental factors, or due to
errors in DNA replication (i.e., not attributable to either heredity or environment).
The sum of these three proportions is 100%. The color codes for hereditary, replicative,
and environmental factors are identical and span white (0%) to brightest red (100%).
B, brain; Bl, bladder; CR, colorectal; E, esophagus; HN, head and neck; K, kidney;
Li, liver; Lk, leukemia; Lu, lung; M, melanoma; NHL, non-Hodgkin lymphoma; P,
pancreas; Pr, prostate; S, stomach; T, testis; Th, thyroid; U, uterus.
than the proportion of cancers preventable by avoiding these factors. Thus,
our estimate that a maximum of 29% of the mutations in these cancers are due
to E is perfectly compatible with the estimate that 42% of these cancers are
preventable, in fact they were based on those epidemiological estimates.
2.5 Discussion
The results described above have important ramifications for understand-
ing the root causes of cancer as well as for minimizing deaths from this disease.
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Our approach - a combination of cancer sequencing data and conservative
analyses of environmental and hereditary risk factors - provides the estimates
of the actual contribution of R mutations to a certain cancer type. They indi-
cated that even in lung adenocarcinomas, R contributes a third of the total
mutations, with tobacco smoke (including second-hand smoking), diet, ra-
diation, and occupational exposures contributing the remainder. In cancers
that are less strongly associated with environmental factors, such as those
of the pancreas, brain, bone, or prostate, the majority of the mutations are
attributable to R.
Our results explicitly and quantitatively address the difference between
cancer etiology and cancer preventability. As illustrated in Figures 2.1 and 2.2,
these concepts are not equivalent. A cancer in which 50% of the mutations are
due to R can still be preventable. The reason for this is that it generally requires
more than one mutation to develop the disease. A cancer that required two
mutations is still preventable if one of the mutations was due to R and the
other due to an avoidable environmental factor.
Our results are fully consistent with epidemiological evidence on the
fraction of cancers in developed countries that are potentially preventable
through improvements in environment and lifestyle. Cancer Research UK
estimates that 42% of cancer cases are preventable (Cancer Research UK,
2018b); the U.S. Centers for Disease Control and Prevention estimates that
21% of annual cancer deaths in individuals less than 80 years old could be
prevented (US Centers for Disease Control and Prevention, 2014).
Of equal importance, these studies provide a well-defined, molecular
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explanation for the large and apparently unpreventable component of cancer
risk that has long puzzled epidemiologists. It is, of course, possible that
virtually all mutations in all cancers are due to environmental factors, most
of which have simply not yet been discovered. However, such a possibility
seems inconsistent with the exhaustively documented fact that about three
mutations occur every time a normal cell divides and that normal stem cells
often divide throughout life.
Our studies complement, rather than oppose, those of classic epidemiology.
For example, the recognition of a third, major factor (R) underlying cancer
risk can inform epidemiologic studies by pointing to cancers that cannot yet
be explained by R (i.e., those with too few stem cell divisions to account for
cancer incidence). Such cancer types seem particularly well suited for further
epidemiologic investigation. Additionally, R mutations appear unavoidable
now, but it is conceivable that they will become avoidable in the future. There
are at least four sources of R mutations in normal cells: quantum effects on base
pairing (Kimsey et al., 2015), mistakes made by polymerases (Kunkel, 2009),
hydrolytic deamination of bases (Fromme and Verdine, 2004), and damage by
endogenously produced reactive oxygen species or other metabolites (Collins,
2005). The last of these could theoretically be reduced by the administration
of antioxidant drugs (Ferguson et al., 2015). The effects of all four could, in
principle, be reduced by introducing more efficient repair genes into the nuclei
of somatic cells or through other creative means.
As a result of the aging of the human population, cancer is today the
most common cause of death in the world (Stewart and Wild, 2014). Primary
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prevention is the best way to reduce cancer deaths. Recognition of a third
contributor to cancer - R mutations - does not diminish the importance of
primary prevention but emphasizes that not all cancers can be prevented by
avoiding environmental risk factors (Figures 2.1 and 2.2). Fortunately, primary
prevention is not the only type of prevention that exists or can be improved
in the future. Secondary prevention, i.e., early detection and intervention,
can also be lifesaving. For cancers in which all mutations are the result of R,
secondary prevention is the only option.
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cancer type female_E female_H female_R male_E male_H male_R both_E both_H both_R
anal 0.6 0.005 0.395 0.6 0.005 0.395 0.6 0.005 0.395
bladder 0.191 0.005 0.804 0.252 0.005 0.743 0.235 0.005 0.76
bone 0 0.005 0.995 0 0.005 0.995 0 0.005 0.995
brain 0.001 0.005 0.994 0003 0.005 0.992 2E-3 0.005 0.993
breast 0.151 0.015 0.834 NA NA NA 0.151 0.015 0.834
cervix 0.746 0.005 0.249 NA NA NA 0.746 0.005 0.249
colon 0.249 0.025 0.726 0.27 0.025 0.705 0.261 0.025 0.714
esophagus 0.628 0.005 0.367 0.596 0.005 0.399 0.606 0.005 0.389
eye 0.003 0.2 0.797 0.021 0.2 0.779 0.012 0.2 0.788
gallbladder 0.079 0.005 0.916 0.08 0.005 0.915 0.079 0.005 0.916
Hodgkin 0.3 0.005 0.695 0.3 0.005 0.695 0.3 0.005 0.695
kidney 0.159 0.01 0.831 0.236 0.01 0.754 0.207 0.01 0.783
larynx 0.693 0.005 0.302 0.716 0.005 0.279 0.709 0.005 0.286
leukemia 0.106 0.005 0.889 0.168 0.005 0.827 0.143 0.005 0.852
liver 0.199 0.005 0.796 0.287 0.005 0.708 0.257 0.005 0.738
lung 0.613 0.005 0.382 0.703 0.005 0.292 0.661 0.005 0.334
melanoma 0.86 0.05 0.09 0.86 0.05 0.09 0.86 0.05 0.09
mesothelioma 0.525 0.005 0.47 0.685 0.005 0.31 0.657 0.005 0.338
myeloma 0.001 0.005 0.994 0.003 0.005 0.992 0.003 0.005 0.993
non-Hodgkin 0.035 0.005 0.96 0.043 0.005 0.952 0.039 0.005 0.956
oral 0.68 0.005 0.315 0.721 0.005 0.274 0.708 0.005 0.287
ovary 0.221 0.05 0.729 NA NA NA 0.221 0.05 0.729
pancreas 0.187 0.05 0.763 0.172 0.05 0.778 0.18 0.05 0.77
penile NA NA NA 0.267 0.005 0.728 0.267 0.005 0.728
prostate NA NA NA 0 0.045 0.955 0 0.045 0.955
stomach 0.509 0.015 0.476 0.576 0.015 0.409 0.553 0.015 0.432
testicular NA NA NA 0 0.005 0.995 0 0.005 0.995
thyroid 0.005 0.015 0.98 0.004 0.015 0.981 0.005 0.015 0.98
uterus 0.181 0.01 0.809 NA NA NA 0.181 0.01 0.809
vaginal 0.42 0.005 0.575 NA NA NA 0.42 0.005 0.575
vulval 0.267 0.005 0.728 NA NA NA 0.267 0.005 0.728
others 0.057 0.005 0.938 0.064 0.005 0.931 0.057 0.005 0.938
oveall 0.278 0.05 0.672 0.299 0.05 0.651 0.289 0.05 0.661
Table 2.1: Proportion of driver gene mutations attributable to E, H, and R Col 1: Cancer
type; Col 2-4: Female; Col 5-7: Male; Col 8-10: Both sexes. The values listed in columns
2, 5, and 8 represent the estimated fraction of the driver gene mutations attributable to
environmental factors, PE, for each indicated cancer type. The values listed in columns 3,
6, and 9 are the estimated fraction of the driver gene mutations attributable to inherited
factors, PH, for each indicated cancer type. The values listed in columns 4, 7, and 10 are
the estimated fraction of the driver gene mutations attributable to replicative mutations,
PR, for each indicated cancer type. The overall values represents the risks for all cancer
types after normalizing for cancer incidence, so that the higher the incidence of the cancer,
the more weight it is given.
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Impact of somatic mutation rate in
cancer etiology
3.1 Introduction
Understanding the etiology of cancer is critical for both its prevention and
its cure (Song et al., 2018). Large scientific evidence has pointed for decades
to the role played by environmental (E) and inherited (H) factors (Cancer
Research UK, 2018; Health, Services, et al., 2004). Recent research has added
a previously unappreciated third factor: the replicative mutations (R) that
accumulate normally in our tissues every time a cell divides (Tomasetti and
Vogelstein, 2015; Tomasetti, Li, and Vogelstein, 2017). It has been estimated
that the majority of the mutations found in cancers are due to this R factor,
when weighting cancer types by their incidence (Tomasetti, Li, and Vogelstein,
2017).
However, independently of whether these mutations are contributed by E,
H, or R, a fundamental but completely unanswered question remains: how
much of cancer is due to mutations?
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The role of driver mutations and other genomic alterations in cancer cau-
sation is well recognized, and much experimental evidence points to their
step-wise accumulation. Thus, mutations certainly represent a necessary in-
gredient for cancer to occur. At the same time, they may not be sufficient, that
is, it is not known how large is their contribution when compared to other
important factors like, for example, the immune system and the microenvi-
ronment. In fact the case may be made that, with aging, several cells will
have acquired the necessary mutations, but only a few or possibly none of
them will end up yielding a cancer. Only those able to overcome the strictly
regulated conditions dictated by their microenvironment, as well as able to
escape the immune system and its protective functions, will. And both E and
H may play a direct role in limiting the ability of the immune system and the
tissue’s microenvironment to provide their functions.
It is then natural to ask how large is the role of driver mutations in cancer
causation when compared to factors like the immune systems, the microen-
vironment, and many other, possibly unknown, ones. More precisely, can
we assess quantitatively how much of the effects of each of the three etiologi-
cal factors, E, H, and R, occur through mutations versus other mechanisms,
which we collectively define as K factors? It is clear that the R acts exclusively
through mutations, by its very definition, but what about E and H factors?
For example, is smoking - a well-known E factor - increasing cancer risk by
simply inducing a higher mutation rate, or rather by damaging the immune
system and other K factors, or both? And if both, is it possible to estimate
those proportions?
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This study represents the first attempt to assess this question. The overall
idea is that we can leverage our knowledge of the effect that a given increase
in the background mutation rate will have in increasing cancer risk. Since we
can estimate the increase in the mutation rate caused by an H or E factor, via
the analysis of sequencing data, we can then estimate the expected increased
risk for a given cancer type, if that H or E factor acted only through its effects
on mutations. The comparison of that expected increase in risk with the
epidemiologically observed relative risk (RR) induced by that E or H factor
will provide then an estimate of the proportion of the actual relative risk
attributable simply to the effects of mutations.
3.2 Method
The probability for a person to develop cancer can be thought of as a
function of multiple factors, including but not limited to, the number of stem
cell divisions, age, the mutation probability per cell division, the immune
system and the microenvironment. Here, we define the mutation rate u in a
stem cell lineage of a given tissue as the number of somatic mutations occurred
in one year in that stem cell lineage. To investigate the role of the mutation
rate in cancer etiology, we propose the following method.
Based on previous results (Tomasetti, Vogelstein, and Parmigiani, 2013;
Tomasetti et al., 2015), the mutation rate u has a multiplicative effect on P,
which is defined as the probability of getting a given cancer for an individual
by age t. Considering P as a function of age, the mutation rate, and all other
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relevant factors, we have
P(t, u) = un f (#stem cells, t, immune system, microenvironment, etc.) (3.1)
where t and u are the age and the mutation rate of that individual, n is the
power-law effect of the mutation rate on cancer risk depending on the number
of drivers required to yield a certain cancer, and f is just the symbol for some
unknown function of all the arguments inside the parenthesis. We note that
n does not have to be an integer. To provide some examples of the possible
values for n, and by assuming that each successive driver gene mutation
doubled the proliferative fitness advantage (Tomasetti et al., 2015; Durrett and
Moseley, 2010), if 2 drivers are required to get to cancer, then n = 2; if 3 drivers
are required, then n = 2.5. While we do not know the exact value of n, it is
easy to show that for solid tumors n should range between 2 and 3 (Tomasetti
et al., 2015). In fact, it has been shown that 2.5 is a good approximation and
certainly the case n = 2 is conservative with respect to our goal of estimating
the contribution of the increase in mutations in explaining relative risk (see
below).
Let K represent the overall average effect on cancer risk other than the
mutation rate, and considering t as the lifespan of an individual, Equation 3.1
can be written as
P(u) = unK (3.2)
Equation 3.2 represents the lifetime risk of getting a certain cancer for an indi-
vidual among the population unexposed to any extrinsic factors (unexposed
population) with an individual-specific mutation rate u. For people who are
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exposed to an extrinsic risk factor E (exposed population), like smoking, their
lifetime risk is
P(u) = unK∗ (3.3)
where K∗ is accounting for all the non-mutational factors which affect risk:
the original ones that were already included in K, plus any additional effects
added by the exposure to the E factor. By writing it in this form, we are able
to separate cancer risk into mutational and non-mutational effects. It can be
inferred that if K∗ ≈ K, then the risk factor E is mostly acting via increasing
the mutation rate, that is by shifting to the right in which case the increase in
mutation rate should be able to explain most of the increased cancer risk.
Assume that g(u) is the density function of the distribution of the mutation






where LRC is the lifetime risk of getting a certain type of cancer for the unex-
posed people. Similarly, LRC∗ for those in the general population exposed to





Let gc(u) be the density function of the distribution of the mutation rate
among the unexposed cancer patients. This can be thought of as a conditional
density of u, i.e. conditional on having cancer, and its relationship with g(u),
the unconditional density, is given by gc(u) =
P(u)g(u)
LRC . Therefore, based on
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Since g(u) is a density function,
∫ +∞
0 g(u)du = 1. Taking the integral from



















One major advantage of using the conditional density to estimate K and K∗ is
that we can use the mutation data from large sequencing studies on cancer
patients, while the information on the whole healthy population is in general
not available. As mentioned earlier, K and K∗ are the average non-mutational
effects on cancer risks. The relative relationship between K∗ and K serves as a
good estimate of the increased risk due to the effects of the E or H factor via
mechanisms other than the mutation rate. Now, the relative risk (RR) of a risk















The relative risk induced by the E or H factor is therefore split into the two pos-
sible pathways through which it can act: mutational (U ) and non-mutational
effects (K). U and K have multiplicative effects on the increased cancer risk.
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We calculate pu, the proportion of increased risk due to the effect on the
mutation rate, using the following formula:
pu =
U − 1
RR − 1 (3.11)
The numerator is the excess relative risk purely due to the increase in the
mutation rate induced by the E or H factor, while the denominator is the
total excess relative risk. On the other hand, we could also calculate pu by
subtracting the proportion due to the increase of non-mutational effects caused
by E or H factor:
pu = 1 −
K− 1
RR − 1 (3.12)
The definition in Equation 3.11 ignores the interaction effects of U and K.
While in Equation 3.12, all the interaction effects are attributed to mutations.
Thus, we define pu as the average from these two expressions.
To estimate pu from the data, the following method based on the Appoxi-
mate Bayesian Computation method (Beaumont, Zhang, and Balding, 2002)
was applied in order to obtain confidence intervals for K∗/K, as well as for the
proportion of increased risk due to the increase in the mutation rate induced
by the E or H factor. The method is described as follows.
Step 1: Sample M values of K∗/K from a prior distribution, in our case a uniform
distribution that depends on the RR for each specific risk factor.
Step 2: For each K∗/K, using bootstrap to get replicates of the distribution of








replicate and obtain the corresponding RR using Equation 3.10.
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Step 3: If the median RR of all replicates with the same K∗/K is within the 95%
confidence interval of the RR from epidemiological studies, then accept
this value of K∗/K; otherwise, reject.
Step 4: All accepted values form the posterior distribution of K∗/K, which is
used to obtain the empirical 95% confidence interval for K∗/K and pu.
3.3 Data
Cancer genome sequencing data from The Cancer Genome Atlas (TCGA)
(The Cancer Genome Atlas, 2018) was used for this analysis. We investigated
4 known risk factors associated with 7 cancer types. There is information on
several other factors/cancer types in the TCGA database. However, since
our method requires density estimations, we excluded from the analysis fac-
tors/cancer types that did not have enough patients out of accuracy concerns.
Risk factors included in this study were smoking, BMI, microsatellite
instability (MSI), and Hepatitis C (HCV) infection. Cancer types included
lung, kidney, head and neck, bladder, liver, uterus, and colon cancers. Patients
with unknown age information were excluded. Before analyzing the data,
some filters were applied to account for potential sequencing errors. Standard
filters were at least 2 but no more than 1000 mutations in total, not higher than
10 times the median mutation rate in the corresponding group. Patients with





3.4.1.1 Lung Adenocarcinoma (LUAD)
TCGA-LUAD data was used to perform the analysis. After removing
all ineligible cases, 62 nonsmokers and 383 smokers were qualified for our
analysis. Comparing to nonsmokers, current male and female smokers are
about 10.8 (95% CI 8.7-13.3) and 4.2 (95% CI 3.5-5) times more likely to de-
velop lung adenocarcinoma respectively (Pesch et al., 2012). This gives an
approximate 7.45 (95% CI 6.06-9.08) times higher risk for current smokers
based on the gender distribution in our data. K∗/K is estimated to be 1.50 or
1.39 with n = 2 or 2.5, yielding the proportions of relative risk in lung cancer
explained by the effect of smoking on the mutation rate as 76.78% (95% CI
68.17%-86.80%) with n = 2 and 80.71% (95% CI 69.85%-92.01%) with n = 2.5.
3.4.1.2 Kidney Renal Cell Carcinoma (RCC)
Since smoking is a risk factor for clear cell and papillary renal cell car-
cinoma (Patel et al., 2015), we used these two subtypes data (TCGA-KIRC
and KIRP) in the analysis. 61 nonsmokers and 51 smokers were analyzed
correspondingly. It is estimated that the increased risk for kidney cancer due
to smoking is 54% (95% CI 42%-68%)) in males and 22% (95% CI: 9%-36%) in
females (Hunt et al., 2005). The relative risk, averaged by genders in the data,
is 1.44 (95% CI: 1.32-1.58). The ratio between K∗ and K, K∗/K, is estimated
to be 0.99 or 0.91 with n = 2 or 2.5, indicating that the increased mutation
rate is able to explain all the increased cancer risk. pu is 100% in both cases,
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with confidence intervals (70.90%, 100%) and (86.36%,100%) for n = 2, 2.5
respectively.
3.4.1.3 Head and Neck Squamous Cell Carcinoma (HNSC)
The majority of head and neck cancers are squamous cell carcinomas. In
terms of the higher risk due to smoking, previous studies have showed that
current smokers have 1.91 (95% CI 1.06-3.42) times higher risk in oral cavity
cancer, 7.49 (95% CI 2.87-19.54) times higher risk in pharyngeal cancer, and
5.26 (95% CI 2.45-11.28) times higher risk in laryngeal cancer (Maasland et
al., 2014). To control for the effects of HPV, this analysis was restricted on
HPV-negative cases. 47 nonsmokers and 216 smokers were finally included.
K ∗ /K is estimated to be 1.2190 and 0.9087 with n = 2 and 2.5. pu is therefore
82.95% (95% CI 50.48%-100%) and 100% (95% CI 62.66%-100%) for n = 2 and
2.5 respectively.
3.4.1.4 Bladder Urothelial Carcinoma (BLAC)
Urothelial bladder carcinoma is the most common type of bladder cancer.
Previous studies suggested a relative risk of 4.06 (95%CI 3.66-4.50) to develop
bladder cancer when comparing smokers with nonsmokers (Freedman et
al., 2011). 108 nonsmokers and 279 smokers were included in the analysis.
K∗/K is estimated to be 1.93 (n=2) and 1.48 (n=3). pu is then 52.81% (95% CI
45.54%-58.01%) assuming n = 2 and 70.72% (95% CI 60.51%-78.62%) assuming
n = 2.5.
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3.4.2 Body Mass Index (BMI)
3.4.2.1 Uterine Corpus Endometrial Carcinoma (UCEC)
The analysis was restricted on patients with uterus cancers who are Mi-
crosatellite Stable (MSS). As a result, 74 normal and 204 obese people were
included in the analysis. Previous study suggested that the relative risk for
uterus cancer is 1.5 (95%CI 1.26-1.78) for BMI from 25-29.9, 2.53 (95%CI 2.02-
3.18) for BMI 30.0-34.9, 2.77 (95%CI 1.83-4.18) for BMI 35.0-39.9, and 6.25
(95%CI 3.75-10.42) for BMI of 40 and above (Calle et al., 2003). This suggests a
relative risk of 3.04 (95% CI 2.20-4.24) based on the BMI distribution in our
data. The calculated K∗/K is 2.62 (n=2) or 2.34 (n=2.5). As a result, pu is 14.15%
(95% CI 8.48%-18.58%) assuming n = 2 or 24.51% (95% CI 15.55%-32.44%).
3.4.2.2 Colon Adenocarcinoma (COAD)
The analysis was performed on microsatellite stable colorectal cancer cases.
Previous study suggests that for female, the relative risk for colon cancer
is 1.10 (95%CI 1.01-1.19) for BMI 25.0-29.9, 1.33 (95%CI 1.17-1.51) for BMI
30.0-34.9, 1.36 (95%CI 1.06-1.74) for BMI 35.0-39.9, and 1.46 (95%CI 0.94-2.24)
for BMI of 40 and above; for male, it is 1.2 (95%CI 1.12-1.30) for BMI 25.0-
29.9, 1.47 (95%CI 1.30-1.66) for BMI 30.0-34.9, and 1.84 (95%CI 1.39-2.41) for
BMI 35 and above ((Calle et al., 2003)). There were 71 normal and 74 obese
cases, and the ratio K∗/K is estimated to be 1.41 (n=2) or 1.44 (n=2.5). What
is the BMI distribution in our data? This indicates that the mutation rate
explain essentially none on the increased cancer risk for colorectal cancer due
to obesity.
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3.4.3 Virus: Hepatitis C (HCV)
3.4.3.1 Liver Hepatocellular Carcinoma (LIHC)
Since the patients in the HCV positive group are all alcohol positive, we
used only alcohol positive within the HCV negative group to control for the
factor of drinking alcohol. Therefore, 74 HCV negative and 153 HCV positive
cases were included in the analysis. Previous study suggested that the relative
risk for liver cancer due to HCV is 33.3 (95% 13.6-81.3) for female, and 17.6
(95% CI 10.7-28.8) for male (Donato et al., 2002). The overall relative risk based
on the gender distribution in the data is 18.75. K∗/K is estimated to be 5.83
(n=2) or 3.73 (n=2.5). As a result, pu is 42.65% (95% CI 38.45%-48.20%) with
n = 2 or 53.68% (95% CI 47.01%-62.84%) with n = 2.5.
3.4.4 Microsatellite instability (MSI)
3.4.4.1 Uterine Corpus Endometrial Carcinoma (UCEC)
Women with mismatch repair deficiency are reported to have a 76.0 (95% CI
56.3-102.5) times the risk of developing endometrial cancer (Stoffel et al., 2009).
To control for the effect of BMI, we only included patients with BMI<=27.5 for
this analysis. Microsatellite instability-high (MSI-h) cancers were defined as
the MSI group. 74 MSS and 39 MSI cases were used to perform the analysis,
which estimates K∗/K as 1.37 (n=2) or 0.65 (n=2.5). Correspondingly, pu is
86.11% (95% CI 76.87%-100%) with n = 2 or 100% with n = 2.5. This means
almost all increased risk caused by MSI is due to an increased mutation rate.
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3.4.4.2 Colon Adenocarcinoma (COAD)
People with mismatch repair deficiency have significant higher risk of
developing colon cancer. The hazard ratio for males is 262.7 (95% CI 214.7-
321.5), for females is 128.0 (95% CI 97.6-168.0) (Stoffel et al., 2009). Only
microsatellite instability-high (MSI-h) cases were included in MSI group. As
a result, 232 MSS and 66 MSI observations were qualified for the analysis.
Considering the gender distribution in the data, the estimated ratio of K∗ and
K is 1.38 (n=2) and 0.38 (n=2.5). pu is then 86.05% (95% CI 78.94%-97.12%)
assuming n = 2 or 100% assuming n = 2.5.
3.5 Discussion
Our study is the first one to quantitatively assess the proportion of the
relative risk caused by an E or H factor that can be explained by their increase
of the mutation rate. The results described above have important indications
on the role of driver mutations in cancer causation.
Among the 4 factors that we have analyzed, smoking and MSI are the
two where an increased mutation rate is able to explain the majority, if not
all, of the increased cancer risk. The results with respect to smoking are not
surprising since scientists have known for decades that smoking cigarettes
causes DNA damage (Pfeifer et al., 2002). And the result for MSI are precisely
what expected, as patients with mismatch repair deficiency are much more
likely to get cancer because they accumulate significantly more mutations
than normal people.
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Figure 3.1: bf Proportion of relative risk explained by the increase of the mutation
rate caused by the indicated E or H factor. Estimate of Pu by assuming that 2 or 3
driver mutations are required for developing cancer, respectively. In smoking and
MSI, the observed increase in the mutation rate is able to explain the majority if
not all of the increased cancer risk. While for BMI, the mutation rate can explain
little about the higher cancer relative risk due to obesity. Cancer types: LUAD
(Lung Adenocarcinoma); RCC (Kidney Renal Cell Carcinoma); HNSC (Head and
Neck Squamous Cell Carcinoma); BLAC (Bladder Urothelial Carcinoma); UCEC-
BMI (Uterine Corpus Endometrial Carcinoma considering BMI); COAD-BMI (Colon
Adenocarcinoma considering BMI); LIHC (Liver Hepatocellular Carcinoma); UCEC-
MSI (Uterine Corpus Endometrial Carcinoma considering MSI); COAD-MSI (Colon
Adenocarcinoma considering MSI)
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The increase in background mutation rate can also partially explain the
higher cancer risk in HCV-positive population. This is also expected when
we look at the mechanisms of carcinogenesis in HCV-associated liver cancers.
Chronic HCV infections are typically associated with inflammatory responses
within the liver, leading to progressive fibrosis and cirrhosis. This, and other
evidence suggesting that HCV can disrupt the control of cellular proliferation,
provide an important mechanism for carcinogenesis, since increasing the rate
of cell division increases the mutation rate. Moreover, evidence shows that
HCV can impair the cell’s response to DNA damage (McGivern and Lemon,
2011). This mutational effect may "hide" some of the mutational consequences
of an HCV infection in causing liver cancer, since the automatic acquisition
of this driver advantage speeds up the process of carcinogenesis therefore
increasing the risk without necessarily leaving a sign on the mutation rate.
Overall, most likely a combination of different factors are responsible for the
progression to liver cancer in HCV-positive patients.
On the other hand, the absence on an increase in mutation rate in obese
people, seems to indicate no role of mutations in increasing cancer risk among
obese people. This needs further investigation and we have ongoing work
testing an association between organ size and obesity.
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Statistical methods for analyzing
liquid biopsy data
4.1 Introduction
Previous study suggests that mutations occurring during normal cell di-
vides (R mutations) are responsible for two-thirds of the mutations in human
cancers(Tomasetti, Li, and Vogelstein, 2017). As a result, many cancers aris-
ing from these unavoidable R mutations are not preventable. From public
health perspective, this poses the challenge of reducing cancer deaths. It
is conceivable that the best way to lower cancer mortality rates is primary
prevention. HPV vaccine is one of the most successful primary prevention
strategies that can significantly reduce the risk of developing HPV-associated
cancers (National Cancer Institute, 2018a). While primary prevention is not
feasible now for all cancer types, we still have secondary prevention, i.e. early
detection and intervention.
Earlier detection is key to reducing cancer deaths. The majority of localized
cancers can be cured by surgery alone, without any systemic therapy (Siegel,
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Miller, and Jemal, 2017). Once distant metastasis has occurred, however,
surgical excision is rarely curative. One major goal in cancer research is
therefore the detection of cancers before they metastasize to distant sites. For
many adult cancers, it takes 20 to 30 years for incipient neoplastic lesions
to progress to late-stage disease (Vogelstein et al., 2013; Jones et al., 2008;
Yachida et al., 2012). Only in the past few years of this long process do
neoplastic cells appear to successfully seed and give rise to metastatic lesions
(Vogelstein et al., 2013; Jones et al., 2008; Yachida et al., 2012; Vogelstein and
Kinzler, 2015). Thus, there is a wide window of opportunity to detect cancers
before the onset of metastasis. Even when metastasis has initiated but is not
yet evident radiologically, cancers can be cured in up to 50% of cases with
systemic therapies, such as cytotoxic drugs and immunotherapy (Bozic et al.,
2013; Semrad et al., 2015; Moertel et al., 1995; Huang et al., 2017). Once large,
metastatic tumors are formed, however, current therapies are rarely effective
(Bozic et al., 2013; Semrad et al., 2015; Moertel et al., 1995; Huang et al., 2017).
The importance of cancer early detection can also be seen from the 5-year
survival rate. For instance, as is shown in Figure 4.1, the 5-year survival rate
for localized lung cancer is 56.3%. However, when the disease has spread to
regional lymph nodes or metastasized, the survival rate drops to 29.7% or
4.7% respectively. On the other hand, when looking at the percentage of cases
at diagnosis, only 16% are localized disease (National Cancer Institute, 2018b).
These facts indicate that we can potentially reduce the cancer mortality rate
significantly by detecting more cancers at earlier stage.
We describe here a new blood test, called CancerSEEK, that can detect eight
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Figure 4.1: Percent of Cases & 5-Year Relative Survival by Stage at Diagnosis:
Lung and Bronchus Cancer SEER 18 2008 - 2014, All Races, Both Sexes by SEER
Summary Stage 2000 (a) 5-year survival by Stage. Localized disease has much higher
survival rate than regional and metastasized cancers. (b) Percent of cases by stage.
Although localized disease has much higher survival rate, it only accounts for 16% of
all lung cancer cases. Source: Surveillance, Epidemiology, and End Results Program
(SEER)
common cancer types (ovary, liver, stomach, pancreas, esophagus, colorectum,
lung, and breast) through assessment of the levels of circulating proteins and
mutations in cell-free DNA, and has the capacity not only to identify the




We began by designing a polymerase chain reaction (PCR)-based assay
that could simultaneously assess multiple regions of driver genes that are
commonly mutated in a variety of cancer types. A 61-amplicon panel, with
each amplicon querying an average of 33 base pairs (bp) within one of 16
genes, was used in the plasma DNA-based tests. As shown in Figure 4.2, this
52
panel would theoretically detect 41% (liver) to 95% (pancreas) of the cancers
in the Catalog of Somatic Mutations in Cancer (COSMIC) data set (Forbes
et al., 2016). In practice, the panel performed considerably better, detecting
at least one mutation in 82%, two mutations in 47%, and more than two
mutations in 8% of the 805 cancers evaluated in our study (Figure 4.2, colored
dots). We were able to detect a larger fraction of tumors than predicted by the
COSMIC data set because the PCR-based sequencing assay we used was more
sensitive for detecting mutations than conventional genome-wide sequencing.
On the basis of this analysis of the DNA from primary tumors, the predicted
maximum detection capability of circulating tumor DNA (ctDNA) in our
study varied by tumor type, ranging from 60% for liver cancers to 100% for
ovarian cancers (Figure 4.2).
Armed with this small but robust panel of amplicons, we developed
two approaches that enabled the detection of the rare mutations expected to
be present in plasma ctDNA. First, we used multiplex-PCR to directly and
uniquely label each original template molecule with a DNA barcode. This
design minimizes the errors inherent to massively parallel sequencing (Kinde
et al., 2011) and makes efficient use of the small amount of cell-free DNA
present in plasma. Additionally, we divided the total amount of DNA recov-
ered from plasma into multiple aliquots and performed independent assays
on each replicate. In effect, this decreases the number of DNA molecules
per well; however, it increases the fraction of each mutant molecule per well,
making the mutants easier to detect. Because the sensitivity of detection is
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Figure 4.2: Development of a PCR-based assay to identify tumor-specific muta-
tions in plasma samples Colored curves indicate the proportion of cancers of the
eight types evaluated in this study that can be detected with an increasing number of
short (< 40 bp) amplicons. The sensitivity of detection increases with the number of
amplicons but plateaus at about 60 amplicons. Colored dots indicate the fraction of
cancers detected by using the 61-amplicon panel used in 805 cancers evaluated in our
study, which averaged 82%. Publicly available sequencing data were obtained from
the COSMIC repository.
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often limited by the fraction of mutant alleles in each replicate, this parti-
tioning strategy allowed us to increase the signal-to-noise ratio and identify
mutations present at lower prevalence than possible if all of the plasma DNA
was evaluated at once. As a result, each individual sample was tested in 6
independent wells, with roughly the same amount of DNA per well.
The second component of CancerSEEK is based on protein biomarkers.
Previous studies have demonstrated that a major fraction of early-stage tumors
do not release detectable amounts of ctDNA, even when extremely sensitive
techniques are used to identify them (Bettegowda et al., 2014; Cohen et al.,
2017). Many proteins potentially useful for early detection and diagnosis of
cancer have been described in the literature (Liotta et al., 2003; Patz Jr et al.,
2007; Wang et al., 2016). We searched this literature to find proteins that
had previously been shown to detect at least one of the eight cancer types
described above with sensitivities >10% and specificities >99%. We found
that 39 of these proteins could be reproducibly evaluated through a single
immunoassay platform, and we then used this platform to assay all plasma
samples.
4.2.2 Challenges in mutation analysis
We were confronted by three competing challenges when developing
the algorithm for the mutation analysis. First, although a more sensitive
approach, as described above, was applied in the sequencing to detect rare
mutations, the PCR errors are unavoidable. It arises from different error-
generating processes, including but not limited to errors introduced during
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PCR amplification to prepare the libraries for capturing or for inverse PCR,
errors introduced by other enzymatic steps, particularly if the enzymes are
impure and contaminated, errors introduced during the shearing process
required to generate small fragments for sequencing, etc.(Kinde et al., 2011)
One critical challenge for the mutation analysis is to separate technical artifacts
from true mutations. Second, for unknown reasons, some positions have
higher background error rates than others. Normalization step is necessary to
adjust for these different error rates before any analysis. Third, the algorithm
should combine the information from 6 independent measurements of each
mutation.
4.2.3 Challenges in protein analysis
We also faced several challenges in protein analysis. First of all, the analysis
should account for the variations in upper and lower limits of detection across
different experiments. Secondly, valid protein biomarkers should be selected
from the original 39 proteins. Thirdly, the algorithm should incorporate
information from both mutation and protein analysis.
4.3 Algorithms for CancerSEEK analysis
4.3.1 Mutation Analysis
4.3.1.1 Normalization
All mutations that did not have more than 1 supermutant (SM) in at
least one well were excluded from the analysis. The mutant allele frequency
(MAF), defined as the ratio between the total number of supermutants in
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each well from that sample and the total number of UIDs in the same well
from that sample, was first normalized based on the observed MAFs for
each mutation in a set of normal controls comprising the normal plasmas
in the training set plus a set of 256 white blood cell samples (WBCs) from
unrelated healthy individuals. All MAFs with <100 UIDs were set to zero. This
normalization was performed by first calculating the average MAF (MAFRe fj )
for each mutation j = 1, · · · , n, found among the normal controls. Using the
25th percentile of the distribution generated by these averages as the reference
value q ≜ Q(14 , MAF
Re f
• ), each MAF was normalized multiplying it by the
ratio q
MAFRe fj
. For example, if the observed average MAF of a mutation in a set
of controls was 10 times higher than q, then each MAF for that mutation was
multiplied by 110 . Assuming total number of samples in the test set m, total






, i = 1, · · · , m; j = 1, · · · , n
If a mutation in a test sample was not observed in any normal control, it was
not normalized, i.e. observed MAF was used for the analysis. In this way,
uniformly high MAFs in certain mutations, if also present in reference set for
any reason, will be reduced. This helps to increase specificity. Standard nor-
malization, i.e. subtracting the mean and dividing by the standard deviation,
did not perform as well according to the cross-validation results.
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Figure 4.3: Distributions of average MAF in the reference set Average MAF by
mutation is calculated for all mutations in the reference set using all qualified wells.
MAF is shown in log scale in the plot.
4.3.1.2 Reference distributions and p-values
Following this mutation-specific normalization, the UID range was split
in 10 intervals (< 1, 000, 1000 − 2000, · · · , 8000 − 9000,> 9000). Groups with
more UIDs tend to have lower MAFs, as is shown in Figure 4.4. This group-
specific distributions enable us to be more sensitive on sample classifications.
Depending on the number of UIDs, the MAF of each mutation in each well
was compared to two reference distributions of MAFs built from samples
in the corresponding UID range: 1) a distribution built from all the normal
control plasmas in the training set plus a set of 256 WBCs from unrelated,
healthy individuals, denoted as DNk , k = 1, · · · , 10; and 2) a distribution built
from the plasma samples from cancer patients in the training set, denoted as
DCk , k = 1, · · · , 10. The cancer training set included only those in which the
same mutation was present in the plasma and in the corresponding primary
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Figure 4.4: Density plot of log MAF in different UID groups Distributions of nor-
mal control MAFs in log scale are shown for UID group 4, 6, and 9 respectively.
The shapes are in general similar, but the means are somewhat different across UID
groups.
tumor, with an MAF > 5% in the tumor. Corresponding p-values, pN and
pC, were thus obtained. The reference distributions for both the normal and
cancer samples were built independently, from the training sets, in each round
and each iteration of 10-fold cross-validation, i.e., 90% of the samples in each
iteration were used for training and 10% of the samples were used for testing.
Specifically, each well of every mutation had 2 p-values,
pNij = Pr(X ≥ MAF
adj
ij |X ∼ DNk , UIDij ∈ UIDgroupk)
pCij = Pr(X ≤ MAF
adj
ij |X ∼ DCk , UIDij ∈ UIDgroupk)
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4.3.1.3 Log ratios and Omega score
For each well, the log ratio of these two pvalues, pCij/p
N
ij was then calcu-
lated, and the minimum and maximum of these log ratios across the six wells
for a mutation were eliminated so that the results would be less sensitive to
outliers. We considered the log ratio of the p-values rather than the standard
log-likelihood ratio because the relatively low number of data points available
did not allow a robust estimation of the densities of the MAF distributions
(particularly for pC). An "Omega" score was then determined according to the
following formula:
Ω = ∑ wi log
pCij
pNij
where wi is the number of UIDs in well i divided by the total number of UIDs
for that mutation in the four wells that were included in the analysis (the two
outlying wells were excluded, as noted above). We weighted the log ratio of
p-values so that those wells containing more template molecules would have
a greater impact on the final statistic (the omega score). The rationale for this
weighting was that the larger the number of template molecules in a well, the
more confidence in the result.
To further illustrate how the omega score is obtained, a specific example of
its calculation is provided in Table 4.1. Consider the KRASp.G12S, c.34G > A
mutation found in sample INDI256PLS1. By eliminating the minimum and
maximum values of those ratios, and applying the above formula for omega,
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Well 1 Well 2 Well 3 Well 4 Well 5 Well 6
SM 161 78 99 84 177 117
UID 3755 2198 2966 2013 3694 3427
MAF 0.043 0.035 0.033 0.042 0.048 0.034
adj MAF 0.0057 0.0047 0.0044 0.0056 0.0064 0.004
pN 1.06e-06 5.70e-06 1.02e-05 1.03e-06 3.09e-07 8.83e-06
pC 0.100 0.124 0.128 0.114 0.094 0.112
ratio( p
C
pN ) 94243 21716 12510 110752 305090 12680
Table 4.1: Example: Mutation analysis
This example illustrate the analysis using KRASp.G12S, c.34G > A mutation
in sample INDI 256 PLS 1. The final omega score for this mutation is 10.6
When a mutation identified in a plasma sample had Ω > 1, and was not
identified in the primary tumor of the patient, we evaluated DNA from white
blood cells (WBCs) of the same patient whenever WBCs were available (23% of
the cancer patients). WBC DNA was tested with the same 61-amplicon panel
to ensure that the plasma mutation was not a result of Clonal Hematopoiesis
of Indeterminate Potential (Jaiswal et al., 2014). WBCs from the normal in-
dividuals were evaluated identically whenever a mutation with Ω > 1 was
found in the plasma. Any mutation that was identified in the WBCs as well as
in the plasma was excluded from the analysis. The requirement for exclusion
was that the ratio between the max MAF in the plasma and the max MAF in
the WBC was less than 100. The mutation with the greatest Ω score in each
patient or normal control was then deemed the "top mutation".
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4.3.2 Protein Analysis
4.3.2.1 Protein’s normalization and transformation
To account for the variations in the lower and upper limits of detection
across different experiments, we set all values smaller than m, defined as
the maximum among all lower limits of detection for a given protein among
all experiments, equal to m. By symmetry, we set all values larger than
M, defined as the minimum among all upper limits of detection for that
protein across all experiments, equal to M. To be conservative, a further
transformation was applied to the proteins levels. Specifically, if a protein’s
concentration in the sample of interest was lower than the 95th percentile
of the concentration found for that same protein among the normal samples
in the training set, then the protein’s concentration was set equal to zero;
otherwise its original concentration value was used. For the Ω score, the same
threshold transformation was used but with a constant threshold equal to 0,
because Ω > 0 indicates an MAF that is more likely to originate from a cancer
than from normal tissue.
4.3.2.2 Combining proteins and mutations
The omega score was used as a feature in logistic regression (LR). The
other 8 features used in LR were the concentrations of the following 8 proteins,
selected from the original 39 proteins via a straightforward optimization:
CA125, CA19-9, CEA, HGF, MPO, OPN, PRL, TIMP-1. The optimization
first eliminated any protein that, according to Mann-Whitney-Wilcoxon test,
had higher median values in normal than in cancer samples, eliminating 13
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proteins and leaving 26 proteins to be evaluated. This was followed by a
forward selection based on the importance of each feature, as evaluated by the
decrease in accuracy of the same logistic regression when that protein alone
was dropped from the remaining 26 protein features. Ten rounds of 10-fold
cross-validations were performed.
4.3.3 Concordance check
For determining the concordance between mutations identified in the
plasma with those identified in primary tumors, we only considered the 153
cases in which a mutation could be identified with high confidence in the
plasma (Ω > 3) and in which the primary tumor contained any mutation that
was present at a mutant allele fraction of > 5%. This approach allowed us to
avoid scoring tumors that had low neoplastic contents (Makohon-Moore et al.,
2017).
4.4 Results
We used CancerSEEK to study 1005 patients who had been diagnosed
with stage I to III cancers of the ovary, liver, stomach, pancreas, esophagus,
colorectum, lung, or breast. No patient received neo-adjuvant chemotherapy
before blood sample collection, and none had evident distant metastasis at
the time of study entry. The median age at diagnosis was 64 (range 22 to
93). The eight cancer types were chosen because they are common in western
populations and because no blood-based tests for their earlier detection are in
common clinical use. The most common stage at presentation was American
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Joint Commission on Cancer (AJCC) stage II, accounting for 49% of patients,
with the remaining patients harboring stage I (20%) or stage III (31%) disease.
The healthy control cohort consisted of 812 individuals of median age 55 (range
17 to 88) with no known history of cancer, high-grade dysplasia, autoimmune
disease, or chronic kidney disease.
The mean sensitivities and specificities were determined by 10 iterations of
10-fold cross-validations. The receiver operating characteristic (ROC) curves
for the entire cohort of cancer patients and controls in one representative
iteration is shown in Figure 4.5.
The median sensitivity of CancerSEEK among the eight cancer types evalu-
ated was 70% and ranged from 98% in ovarian cancers to 33% in breast cancers
(Figure 4.5C). At this sensitivity, the specificity was >99%; only 7 of the 812
individuals without known cancers scored positive. We could not be certain
that the few false positive-testing individuals identified among the healthy
cohort did not actually have an as-yet undetected cancer, but classifying them
as false positives provided the most conservative approach to classification
and interpretation of the data.
One of the most important attributes of a screening test is the ability to
detect cancers at relatively early stages. The median sensitivity of CancerSEEK
was 73% for the most common stage evaluated (stage II), similar (78%) for
stage III cancers, and lower (43%) for stage I cancers (Figure 4B). The sensitivity
for the earliest-stage cancers (stage I) was highest for liver cancer (100%) and
lowest for esophageal cancer (20%).
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Figure 4.5: Performance of CancerSEEK (A) ROC curve for CancerSEEK. The red
point on the curve indicates the test’s average performance (62%) at >99% specificity.
Error bars represent 95% confidence intervals for sensitivity and specificity at this
particular point. The median performance among the eight cancer types assessed was
70%. (B) Sensitivity of CancerSEEK by stage. Bars represent the median sensitivity
of the eight cancer types, and error bars represent standard errors of the median.




We have designed a multi-analyte blood test that can detect the presence
of eight common solid tumor types. The advantage of combining completely
different agents, with distinct mechanisms of action, is widely recognized in
therapeutics (Organization and Organization), 2010; Organization et al., 2016;
Benson et al., 2017) but has not been routinely applied to diagnostics. We
combined protein biomarkers with genetic biomarkers to increase sensitivity
without substantially decreasing specificity. Other cancer biomarkers-such
as metabolites, mRNA transcripts, miRNAs, or methylated DNA sequences-
could be similarly combined to increase sensitivity and localization of cancer
site. Such multi-analyte tests are not meant to replace other non-blood-based
screening tests, such as those for breast or colorectal cancers, but to provide
additional information that could help identify those patients most likely to
harbor a malignancy.
Several limitations of our study should be acknowledged. First, the pa-
tient cohort in our study was composed of individuals with known cancers,
most diagnosed on the basis of symptoms of disease. Although none of our
patients had clinically evident metastatic disease at the time of study entry,
most individuals in a true screening setting would have less advanced dis-
ease, and the sensitivity of detection is likely to be less than reported here.
Second, our controls were limited to healthy individuals, whereas in a true
cancer screening setting, some individuals might have inflammatory or other
diseases, which could result in a greater proportion of false-positive results
than observed in our study. Third, although multiple-fold cross-validation is
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a powerful and widely used technique for demonstrating robust sensitivity
and specificity on a cohort of this study’s scale, we were not able to use a com-
pletely independent set of cases for testing, which would have been optimal.
Last, the proportion of cancers of each type in our cohort was purposefully not
representative of those in the United States as a whole because we wanted to
evaluate at least 50 examples of each cancer type with the resources available
to us. When weighted for actual incidence in the United States, we estimate
the sensitivity of CancerSEEK to be 55% among all eight cancer types. This
weighting would not affect the high sensitivities of CancerSEEK (69 to 98%)
to detect five cancer types (ovary, liver, stomach, pancreas, and esophagus)
for which there are no screening tests available for average-risk individuals.
Our study lays the conceptual and practical foundation for a single, multi-
analyte blood test for cancers of many types. We estimate the cost of the
test to be less than $500, which is comparable or lower than other screening
tests for single cancers, such as colonoscopy. The eight cancer types studied
here account for 360,000 (60%) of the estimated cancer deaths in the United
States in 2017, and their earlier detection could conceivably reduce deaths
from these diseases. To actually establish the clinical utility of CancerSEEK
and to demonstrate that it can save lives, prospective studies of all incident
cancer types in a large population will be required.
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Chapter 5
Conclusion and Future work
In this dissertation, we proposed novel approaches to address the impor-
tance of random mutations in cancer causation, and developed methods for
analyzing liquid biopsy data for cancer early detection.
Specifically, in Chapter 2, we used genome sequencing and epidemiological
data to determine the proportions of cancer-causing mutations that result from
inherited (H), environmental (E), and replicative factors (R) (Tomasetti, Li,
and Vogelstein, 2017). Our results highlight the prominent role of R mutations
in cancer etiology and conclude that a substantial amount of cancer-causing
mutations are actually due to the random replicative errors. These findings are
consistent with the epidemiological evidence on the fraction of preventable
cancers, and in fact, provide a well-defined, molecular explanation for the
large and apparently unpreventable component of cancer risk that has long
puzzled epidemiologists.
The above result consider exclusively mutations. However, independently
of whether these mutations are contributed by E, H, or R, a fundamental
but completely unanswered question remains: how much of cancer is due to
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mutations? In Chapter 3, we sought to estimate the proportions of increased
cancer risk that can be explained by the increased mutation rate. Our results
suggest that mutations account for an extremely large proportion of the higher
risk due to smoking and microsatellite instability (MSI), a relatively large
proportion in Hepatitis C infections, but almost nothing in obesity. Future
work is needed to understand what is the mechanism through which obesity
works in increasing cancer risk.
These two studies point to the fact that not all cancers are preventable
due to the unavoidable R mutations. Therefore, in Chapter 4, we developed
statistical methods for CancerSEEK, a multi-analyte blood test for cancer early
detection (Cohen et al., 2018). With 99% specificity, our sensitivities ranged
from 69% to 98% for the detection of five cancer types (ovary, liver, stomach,
pancreas, and esophagus) for which there are no screening tests available for
average-risk individuals.
While the majority of cancer research is focused on curing late stage dis-
eases, the data from CancerSEEK study presents promising result on detecting
early cancer cases using a blood-based test. However, due to the low disease
prevalence, it should be evaluated using large clinical trials in a real-word
setting before being approved as a clinically useful screening test. In addition,
the sensitivities vary across different cancer types and different stages. Look-
ing at the sensitivities, it is clear that we have a large room for improvement,
like for breast cancer and stage I disease. It is also worthwhile to mention that
even though the test has a very high specificity (>99%), it is likely that we will
still have a substantial amount of false positives when applying the screening
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test in the general population due to the low disease prevalence.
Although in CancerSEEK we analyzed mutations from ctDNA and pro-
tein biomarkers, there are also other panels that can potentially increase the
sensitivity of the test, including but not limited to, assay for aneuploidy (Adal-
steinsson et al., 2017), tissue-specific DNA methylation patterns (Snyder et al.,
2016). Combining multiple blood-based analytes to achieve optimal sensitivi-
ties, while maintaining cost-effective and high specificity as a screening test,
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